In this study, we conducted a pooled analysis of current data to evaluate the clinical efficacy of second‐ or later‐line therapies for ESCC patients and to explore the potential of PD‐1 inhibitor‐based combination therapies compared with previous standard treatments. Here, PDCD1 is linked to esophageal squamous cell carcinoma.